Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Durvalumab + Chemotherapy in Resected Stage II-III NSCLC (MERMAID-1)
NCT04385368Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 33
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04385368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385368.